Skip to main content
. 2019 Oct 8;12(1):72–85. doi: 10.4168/aair.2020.12.1.72

Table 4. Comorbidities according to AR classifications.

Comorbidities of AR aOR* (95% CI)
Mild Moderate to severe
Intermittent Persistent Intermittent Persistent
No./total No. (%) aOR* (95% CI) No./total No. (%) aOR* (95% CI) No./total No. (%) aOR* (95% CI) No./total No. (%) aOR* (95% CI)
Current asthma 7/177 (3.9) 18.48 (2.11–161.88) 2/46 (4.3) 16.63 (1.34–207.13) 6/19 (31.6) 331.66 (27.26–4,035.98) 3/34 (8.8) 41.01 (3.62–464.15)
PC20 < 8 mg/mL 31/152 (20.4) 2.29 (1.27–4.14) 6/46 (13.0) 0.92 (0.32–2.65) 6/17 (35.3) 4.45 (1.39–14.27) 9/31 (29.0) 3.91 (1.50–10.23)
BHR without current asthma 28/149 (18.8) 2.18 (1.18–4.02) 5/45 (11.1) 0.99 (0.34–2.84) 2/13 (15.4) 1.48 (0.29–7.53) 8/30 (26.7) 3.54 (1.30–9.67)
Current eczema 42/92 (45.7) 3.06 (1.45–6.45) 6/15 (40.0) 1.00 (0.25–3.92) 4/10 (40.0) 2.14 (0.49–9.45) 7/16 (43.8) 2.54 (0.69–9.33)
Allergic sensitization 76/168 (45.2) 1.46 (0.94–2.25) 25/45 (55.6) 2.08 (1.01–4.27) 8/15 (53.3) 1.65 (0.55–4.99) 21/32 (65.6) 2.58 (1.12–5.94)

Control group for AR: all subjects who have never been diagnosed with AR by a physician.

AR, allergic rhinitis; aOR, adjusted odds ratio; CI, confidence interval; BHR, bronchial hyperresponsiveness.

*Adjusted by sex, maternal education levels, parental history of allergic diseases, history of second-hand smoking, residential area, and economic status; P < 0.05; P < 0.01.